Has Han Phan received payments from drug or device companies?

Yes. Drug and device makers reported $44,059 in general payments to Han Phan across 46 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Han Phan did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Han Phan come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Han Phan

Neurology with Special Qualifications in Child Neurology · Atlanta, GANPI 1306954037

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $38,775 of the $44,059 with a category attached, or 88.0%. Sarepta Therapeutics, Inc. accounts for 70.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $23,194 and has fallen 99.8% since, to $45 in 2025.

$44,059in general payments, 2019–2025

Across 46 payments — averaging $957.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sarepta Therapeutics, Inc.$31K
Genentech USA, Inc.$7K
Biogen$5K
Genentech, Inc.$132
NS Pharma, Inc.$110
Insmed, Inc.$88
plus $78 from 1 others

$16,360,548in research payments, 2019–2025

Across 1,429 payments — averaging $11,449 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sarepta Therapeutics, Inc.$6.4M
Applied Therapeutics, Inc.$5.2M
Takeda Pharmaceuticals U.S.A., Inc.$1.2M
Ultragenyx Pharmaceutical Inc.$1M
Biogen$557K
PTC Therapeutics, Inc.$423K
plus $1.5M from 21 others

What the payments were for

Consulting fees$38,77588%
Travel & lodging$4,0719%
Food & beverage$1,2133%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sarepta Therapeutics, Inc.	31	$31,248
Genentech USA, Inc.	3	$7,315
Biogen	5	$5,088
Genentech, Inc.	1	$132
NS Pharma, Inc.	1	$110
Insmed, Inc.	2	$88
Pfizer	3	$78

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EVRYSDI$7,447
SPINRAZA$5,015
VILTEPSO$110

How this compares

$44,059 in reported general payments places this provider in the 85th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.

See all neurology with special qualifications in child neurology providers in Georgia →

Other neurology with special qualifications in child neurology in Atlanta

Chaouki KhouryAtlanta$978K
Raymond ChengAtlanta$40K
Sonam BhallaAtlanta$23K
Cherise FrazierAtlanta$9K
Howard SchubAtlanta$7K
Ton de GrauwAtlanta$4K
Jamika Hallman-CooperAtlanta$2K
Moira BlackAtlanta$1K
Jenny LinAtlanta$1K
Kishore VedalaAtlanta$733

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →